DB-1303/BNT323 not checked

DualityBio Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Breast Cancer, HER2-positive Breast Cancer, HER2-positive Advanced Solid Tumor
Main trialPhase 3
“The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.”In the company’s words, NCT06018337 on ClinicalTrials.gov

Other drugs for Metastatic Breast Cancer

All 397 drugs for Metastatic Breast Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 12 Aug 2026 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Phase 3Active, not recruiting Dec 2027 A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
Phase 1/2Recruiting Aug 2027 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DB-1303/BNT323

Following is part of Solo: you see every change to DB-1303/BNT323 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in